Logo
x

Search

Subscribe Now

daiichi sankyo

Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NSCLC

Daiichi Sankyo and AstraZeneca Dose the First Patient with Adjuvant Datroway in P-III (TROPION-Lung12) Trial for Adenocarcinoma NS...

  • January 31, 2025
Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progressed on Endocrine Therapies

Daiichi Sankyo and AstraZeneca Report the US FDA’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC), Progr...

  • January 28, 2025
Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Receives the US FDA Approval for Datroway (Datopotamab Deruxtecan-dlnk) to Treat HR+/HER2- Metastat...

  • January 20, 2025
Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

Daiichi Sankyo’s Datroway Receives the MHLW’s Approval for Unresectable or Recurrent HR+/HER2- Breast Cancer

  • December 27, 2024
Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (AML)

Daiichi Sankyo Begins the P-III (QuANTUM-Wild) Study of Vanflyta (Quizartinib) to Treat FLT3-ITD Negative Acute Myeloid Leukemia (...

  • December 11, 2024
Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

Daiichi Sankyo Reports Pooled Analysis from TROPION-Lung05 & TROPION-Lung01 Trials of Datopotamab Deruxtecan (Dato-DXd) for NSCLC

  • December 6, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.